Business
Aurinia Announces Results of the 2021 Annual General Meeting
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":" VICTORIA, British Columbia--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting (the “Meeting”) held on June 7, 2021.\n\nDetailed results of the vote by proxy for the election of directors are provided below:\n\n\n\nNominee\n\n\n \n \n \n\nVotes For (%)\n\n\n \n \n \n\nVotes Withheld (%)\n\n\n\n\n\nGeorge M. Milne\n\n\n \n \n \n\n80.91\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n19.09\n\n\n\n\n\nPeter Greenleaf\n\n\n \n \n \n\n92.18\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n7.82\n\n\n\n\n\nDavid R.W. Jayne\n\n\n \n \n \n\n93.00\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n7.00\n\n\n\n\n\nJoseph P. Hagan\n\n\n \n \n \n\n87.15\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n12.85\n\n\n\n\n\nDaniel G. Billen\n\n\n \n \n \n\n95.64\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n4.36\n\n\n\n\n\nR. Hector MacKay-Dunn\n\n\n \n \n \n\n93.27\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n6.73\n\n\n\n\n\nJill Leversage\n\n\n \n \n \n\n95.05\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n4.95\n\n\n\n\n\nTimothy P. Walbert\n\n\n \n \n \n\n89.56\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n10.44\n\n\n\n\nIn addition, following final tallies of votes, all other matters voted on at the Meeting were also approved. Voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com.\n\nAbout Aurinia\n\nAurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210607005782/en/\n\nInvestors:\nGlenn Schulman, PharmD, MPH\nInvestor Relations & Corporate Communications, Aurinia\[email protected]\n\nMedia:\nDana Lynch\nCorporate Communications, Aurinia\[email protected] \n\nSource: Aurinia Pharmaceuticals Inc.","length":16432,"tagName":"div"}]